Drug firm Glenmark Pharmaceuticals, under the brand name FabiFlu, has launched an antiviral drug Favipiravir, to cure patients with mild to moderate coronavirus at a price tag of about Rs 103 per tablet. According to Glenmark Pharmaceuticals, the medication will be available in the form of a 200 mg tablet and will be at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets. With this FabiFlu also becomes the first oral favipiravir-approved medication for the treatment of COVID-19 in India, it further stated. "Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the 1st month itself." As the coronavirus cases in India continue to spread rapidly, India is now just behind the United States, Brazil, and Russia in terms of the total confirmed cases.

Source: dna June 22, 2020 09:11 UTC